Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: Cogito Ergo Sum who wrote (177334)	8/27/2021 9:00:43 AM
From: TobagoJack	1 Recommendation Recommended By marcher Respond to of 217657

Team China turning vaccine variants out like hot cakes One of the many ought to work for something or other Letting 100 flowers bloom And, no, I do not for a moment ceased to suspect that the mRNA and directed vector liquids work a Felty In comparison, the mRNA vaccines from Pfizer Inc. and Moderna have largely held up well against variants, including the delta strain that was first found in India and has spread to more than 100 countries around the world. bloomberg.com New China Vaccine Shows 82% Effectiveness Against Serious Covid August 27, 2021, 7:43 PM GMT+8 A vaccine from China’s Chongqing Zhifei Biological Products Co. showed 82% effectiveness against serious Covid-19 infections, boosting the country’s efforts to immunize its vast population. In late-stage clinical trials, the vaccine -- dubbed ZF2001 -- has been shown as 92.93% effective against the alpha variant and almost 78% against the more-infectious delta version, the company said in an exchange filing Friday. It did not say if those two figures were just for serious illness or all symptomatic infections including mild cases. None of the people who received the shot entered critical care or died, it said. The results were based on an interim analysis of 221 number of infections in the study of 28,500 people. Zhifei’s shot is the fifth developed inside China that has been validated in a large clinical trials done in places still battling outbreaks. The vaccine was co-developed with the Institute of Microbiology at the Chinese Academy of Sciences, the country’s top scientific research organ, and the efficacy against alpha variant appears to be one of the highest among all Chinese Covid-19 vaccines so far. World’s Fastest Growing Fortune Is a Chinese Pharma Tycoon Zhifei launched the phase III trials, the final study required before gaining authorization, for the experimental shot in December in Uzbekistan, and kicked off testing in Pakistan in February. The vaccine is also being tested in Ecuador and Indonesia. China approved the vaccine for emergency use on March 10 and it’s now among several being administered across the nation. The vaccine uses a similar technology as Novavax Inc.’s shot, which boasts a 90% efficacy against symptomatic Covid but has appeared to be far less effective in an earlier study against the beta variant. In comparison, the mRNA vaccines from Pfizer Inc. and Moderna have largely held up well against variants, including the delta strain that was first found in India and has spread to more than 100 countries around the world. — With assistance by John Liu, Dong Lyu, and Chunying Zhang Before it's here, it's on the Bloomberg Terminal. LEARN MORE Sent from my iPad